CN109350622A - The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt - Google Patents
The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt Download PDFInfo
- Publication number
- CN109350622A CN109350622A CN201811207017.9A CN201811207017A CN109350622A CN 109350622 A CN109350622 A CN 109350622A CN 201811207017 A CN201811207017 A CN 201811207017A CN 109350622 A CN109350622 A CN 109350622A
- Authority
- CN
- China
- Prior art keywords
- pyrroloquinoline quinone
- niacinamide
- food
- kinds
- sodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 title claims abstract description 114
- -1 niacinamide core carbohydrates Chemical class 0.000 title claims abstract description 23
- 159000000000 sodium salts Chemical class 0.000 title claims abstract description 23
- 235000014633 carbohydrates Nutrition 0.000 title claims abstract description 21
- 238000005516 engineering process Methods 0.000 title claims abstract description 13
- 229950006238 nadide Drugs 0.000 claims abstract description 67
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 67
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000011570 nicotinamide Substances 0.000 claims abstract description 54
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 54
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 53
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 51
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims abstract description 45
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 45
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract description 45
- 230000003796 beauty Effects 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 29
- UFVBOGYDCJNLPM-UHFFFAOYSA-L disodium;9-carboxy-4,5-dioxo-1h-pyrrolo[2,3-f]quinoline-2,7-dicarboxylate Chemical compound [Na+].[Na+].C12=C(C([O-])=O)C=C(C([O-])=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 UFVBOGYDCJNLPM-UHFFFAOYSA-L 0.000 claims abstract description 22
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 20
- 235000020956 nicotinamide riboside Nutrition 0.000 claims abstract description 20
- 239000011618 nicotinamide riboside Substances 0.000 claims abstract description 20
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 10
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract 6
- 230000036541 health Effects 0.000 claims description 21
- 150000001412 amines Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000000295 complement effect Effects 0.000 abstract description 5
- 230000003712 anti-aging effect Effects 0.000 abstract description 4
- 235000013373 food additive Nutrition 0.000 abstract description 4
- 239000002778 food additive Substances 0.000 abstract description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 65
- 239000000047 product Substances 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 6
- 150000003233 pyrroles Chemical class 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- AWJZMUKFUBQPRP-UHFFFAOYSA-N quinoline;sodium Chemical compound [Na].[Na].N1=CC=CC2=CC=CC=C21 AWJZMUKFUBQPRP-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- KFAIBFISQIXYLE-UHFFFAOYSA-N [Na].[Na].N=1C(C(C=C2C=CC=CC12)=O)=O Chemical compound [Na].[Na].N=1C(C(C=C2C=CC=CC12)=O)=O KFAIBFISQIXYLE-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its group technologies of sodium salt, including niacinamide ribose (NR) (chloride, or nicotinamide riboside), β-nicotinamide mononucleotide (NMN), nicotinamide adenine dinucleotide (NADH), four kinds of different compounds of pyrroloquinoline quinone disodium salt (PQQ), by above-mentioned four kinds different compounds with any 2 kinds, any 3 kinds or all 4 kinds are combined into a formula, it is made into food, health food, beauty product or drug, with external application, oral or injection mode, it plays a role in into human body.Its niacinamide core carbohydrates and their derivative has the function of anti-aging, pyrroloquinoline quinone and its sodium salt have the function of similar, it is functionally complementary with niacinamide ribose, pass through niacinamide ribose or derivatives thereof, with pyrroloquinoline quinone or its sodium salt combination formula, the products such as food additives, health food, beauty product and drug are made into, achieve the purpose that delaying human body caducity, beauty or treatment disease.
Description
Technical field
The present invention relates to pharmaceutical technology fields, specially niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt
Group technology.
Background technique
Niacinamide ribose (NR) (chloride) (English name: nicotinamide riboside, abbreviation NR) is also niacinamide
Nucleosides, CAS 23111-00-4.Niacinamide ribose is one kind of vitamin B3 cluster, is important two core of coenzyme nicotinamide adenine
The precursor of thuja acid.
Nicotinamide adenine dinucleotide (cozymase, English: Nicotinamide adenine dinucleotide, letter
Claim: NADH).The cofactors are because have support of six Nobel Laureate to its correlative study, thus also referred to as " promise adds
The factor " is a kind of coenzyme for passing on proton (being hydrogen ion for more acurrate), it participates in cellular material metabolism, energy synthesizes, thin
A variety of physiological activities such as born of the same parents DNA reparation.Niacinamide ribose is present in milk, fruit etc. in nature, but content is extremely low, institute
With source is very limited.Niacinamide ribose is unstable at normal temperature, is easy to decompose, and stablizes under the villaumite room temperature of niacinamide ribose,
So actual use is substantially niacinamide ribose villaumite.
β-nicotinamide mononucleotide (NMN) (English name: β-nicotinamide mononucleotide, abbreviation NMN)
CAS 1094-61-7 is important the precursor of coenzyme NAD H (nicotinamide adenine dinucleotide).In the cell, niacinamide core
NMN is formed after Sugar phosphorylation, NMN is then converted to NADH (nicotinamide adenine dinucleotide).Therefore, functionally, NR is almost
It is identical as NMN.
Pyrroloquinoline quinone disodium salt (English name: pyrroloquinoline quinone disodium salt, or
Methoxatin, abbreviation PQQ) CAS 122628-50-6, PQQ as a kind of new type water-solubility vitamin, be a kind of redox
Enzyme prothetic group, it is very rare, is present in some microorganisms, in plant and animal tissue, is not only involved in catalysis biological vivo oxidation
Reduction reaction, but also there are some special bioactivity and physiological function；
Pyrroloquinoline quinone (English name: pyrroloquinoline quinone, abbreviation PQQ) CAS 72909-34-3, function
Can be identical as pyrroles's quinoline disodium salt, still, there is no pyrroles's quinoline disodium salt to stablize under room temperature.
In human body, niacinamide ribose chloride can be hydrolyzed into niacinamide ribose, after niacinamide ribose is absorbed by cell,
It is converted into nicotinamide mononucleotide (NMN), NMN generates nicotinamide adenine dinucleotide (NADH) again, plays a role.So
Niacinamide ribose (NR), nicotinamide mononucleotide (NMN) and nicotinamide adenine dinucleotide (NADH) these three compounds are all
Can individually or two kinds, three kinds of any combination, as functional component, supplement plays a role into the human body.They can divide
Sub- level allows intracellular mitochondria (mitochondria) to rejuvenate, and provides more energy for cell, allows the thin of aging
Born of the same parents return to the level of normal cell.
Pyrroloquinoline quinone (PQQ) or pyrroles's quinoline disodium salt (being referred to as also PQQ), an important work in the cell
With being the generation that can promote new mitochondria.So at this point, PQQ is different with NR, NMN, NADH, in function
On be complementary.There are no be combined into niacinamide core carbohydrates and their derivative with pyrroloquinoline quinone and its sodium salt to match on the market at present
Side is in food, beauty product and drug.
Summary of the invention
The purpose of the present invention is to provide niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its combination works of sodium salt
Skill, niacinamide core carbohydrates and their derivative has the function of anti-aging, and has the function of prevention and treatment to a variety of diseases, leads to
Cross niacinamide ribose or derivatives thereof, and pyrroloquinoline quinone or its sodium salt combination formula, be made into food additives, health food,
The products such as beauty product and drug achieve the purpose that delaying human body caducity, beauty or treatment disease, to solve above-mentioned background skill
The problem of being proposed in art.
To achieve the above object, the invention provides the following technical scheme: niacinamide core carbohydrates and their derivative and pyrroles's quinoline
The group technology of quinone and its sodium salt, including niacinamide ribose (NR) (chloride or nicotinamide riboside), β-niacinamide monokaryon glycosides
Acid (NMN), four kinds of nicotinamide adenine dinucleotide (NADH), pyrroloquinoline quinone disodium salt (PQQ) different compounds, will be upper
State four kinds of different compounds and be combined into a formula with any 2 kinds, any 3 kinds or all 4 kinds, be made into food, health food,
Beauty product perhaps drug in a manner of external application, oral or injection, into human body in play a role.
As the further technical solution of the present invention, pyrroloquinoline quinone disodium salt (PQQ) can be used identical as its function
Pyrroloquinoline quinone (PQQ) replace.
As the further technical solution of the present invention, niacinamide ribose (NR) (chloride or nicotinamide riboside) exists
The dosage of single component or daily dosage range are as follows in combination formula: single dose 1mg to 100000mg, daily agent
Amount or limited amount 1mg to 100000mg, including the application in food, health care product, beauty product and drug.
As the further technical solution of the present invention, β-nicotinamide mononucleotide (NMN) in combination formula it is single at
Point dosage perhaps daily dosage range is as follows: single dose 1mg to 100000mg daily dosage or limited amount 1mg
To 100000mg, including the application in food, health care product, beauty product and drug.
As the further technical solution of the present invention, nicotinamide adenine dinucleotide (NADH) is single in combination formula
Perhaps daily dosage range is as follows for the dosage of one ingredient: single dose 1mg to 100000mg daily dosage or limited amount
1mg to 100000mg, including the application in food, health care product, beauty product and drug.
As the further technical solution of the present invention, pyrroloquinoline quinone disodium salt (PQQ) in combination formula it is single at
Point dosage perhaps daily dosage range is as follows: single dose 1mg to 100000mg daily dosage or limited amount 1mg
To 100000mg, including the application in food, health care product, beauty product and drug.
Compared with prior art, the beneficial effects of the present invention are:
The group technology of niacinamide core carbohydrates and their derivative provided by the invention and pyrroloquinoline quinone and its sodium salt, nicotinoyl
Amine core carbohydrates and their derivative includes niacinamide ribose (NR) (chloride or nicotinamide riboside), β-nicotinamide mononucleotide
(NMN), nicotinamide adenine dinucleotide (NADH) has the function of anti-aging, and has prevention and treatment to a variety of diseases
Effect；Pyrroloquinoline quinone and its sodium salt have the function of similar, and are functionally complementary to one another, pass through with niacinamide ribose
Niacinamide ribose or derivatives thereof is made into food additives, health food, beauty with pyrroloquinoline quinone or its sodium salt, combination formula
Hold the products such as product and drug, achievees the purpose that delaying human body caducity, beauty or treatment disease.
Specific embodiment
It will be detailed below the embodiment of the present invention, however, the embodiment of the present invention is not limited thereto.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts,
It shall fall within the protection scope of the present invention.
In the embodiment of the present invention: the combination work of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt is provided
Skill, including niacinamide ribose (NR) (chloride or nicotinamide riboside), β-nicotinamide mononucleotide (NMN), nicotinoyl amine gland are fast
Four kinds of nicotinamide adenine dinucleotide (NADH), pyrroloquinoline quinone disodium salt (PQQ) different compounds, by above-mentioned four kinds different compounds with
Any 2 kinds, it is any 3 kinds perhaps all 4 kinds be combined into a formula and be made into food, health food, beauty product or drug,
In a manner of external application, oral or injection, into human body in play a role.
Wherein, No. CAS niacinamide ribose for 1341-23-7, it is unstable at normal temperature, without business use value, and
Niacinamide ribose villaumite (CAS 23111-00-4 or nicotinamide riboside) is very stable at normal temperature, and on kinetic energy almost without
Any change, so, niacinamide ribose generally is exactly its villaumite, first after oral niacinamide ribose is absorbed by the body
First will be by liver, because niacinamide ribose has preferable penetrability to cell membrane, most of niacinamide ribose is passing through liver
Absorbed when this necessary approach of capillary by liver cell, do not enter into blood circulation, so, by oral administration after can examine in blood
The niacinamide Ribose concentration measured is not high, and niacinamide ribose is transformed into niacinamide ribomononucleoside first in liver cell
(NMN), then it is transformed into nicotinamide adenine dinucleotide (NADH), plays the effect of coenzyme.So niacinamide ribose is main
Effect organ is liver, can improve the function of liver cell, so obvious to the no liver of effect on other organs.Also there is small portion
Other positions for dividing niacinamide ribose that can be transported to human body by blood circulation play a role, wherein oral niacinamide core
Sugar is partially broken down into niacinamide in human body alimentary canal, and can enter blood circulation, so, by oral administration after can examine quickly
The content for measuring niacinamide in blood increases.
Wherein, the precursor of niacinamide ribomononucleoside (NMN) is NR, and still, it is straight by cell that NMN cannot pass through cell membrane
Absorption is connect, oral NMN is most of unlike NR to be absorbed by liver cell, but is distributed to whole body with blood circulation.So warp
It can detect that NMN content increases after oral in blood quickly, be transported to the NMN of human body everywhere before entering cell,
It extracellularly must be inversely converted into NR, enter back into cell.Portion in the cell is then converted to NMN.In terms of the uniformity of distribution,
NR is not so good as NMN.But the function of the two is played a role by generating NADH, it is each advantageous.Improve liver function,
The effect of NR is better than NMN；If NR and NMN, NR is used to avoid gastral destruction and liver by the way of injection
Primary absorption process, what NR can be more uniform is distributed to whole body.Moreover, because NR can enter cell directly through cell membrane,
So NR ratio NMN is more advantageous when injection uses；NR or NMN is either supplemented, is played a role by NADH,
NADH is unique substance that cellular energy can be improved Jing Guo scientific appraisal, can improve body constitution, improves immunity, is reduced
The risk of disease.In addition to this, NADH also possesses different physiological roles, such as: protection and DNA plerosis are reduced caused by DNA mutation
Cancer；Reduce the biochemical inducement of a variety of diseases such as artery sclerosis, rheumatic arthritis, diabetes；As powerful antioxidant, resist
Free radical is injured caused by human body；Reduce the risk of cholesterol, hypertension；The generation of adrenaline and dopamine is excited, it is right
Anti-Parkinson and Alzheimer disease；Promote nitric oxide production synthesis, to the adjustment effect of muscle, brain and its hetero-organization, has
Conducive to cardiovascular and cerebrovascular especially angina pectoris, heart infarction, the treatment of cerebral infarction etc., the NADH content in cell is higher, the function of mitochondria
Stronger, generated energy is more, and the function of cell is better, so that cell itself and the health status of entire human body are just
Better, the service life is longer.
Wherein, nicotinamide adenine dinucleotide (NADH) is although NADH can directly play a role, point of NADH
Son is almost that twice of NMN is big, it is more difficult to pass through cell membrane.Moreover, being largely decomposed when oral NADH, directly utilized by cell
It is few, if using injection by the way of, how there is also equally pass through cell membrane.But it is demonstrated experimentally that human body mouth
After taking NADH, the NADH content in blood is increased, and may have small part directly to be absorbed, the NADH of a small amount of external source is directly inhaled
After receipts, it can play a role immediately.Therefore, directly supplement NADH is also an effective means；During energetic supersession, NADH
Become NAD+ after being oxidized, NAD+ can also be reduced to NADH.The ratio of NAD+/NAD is in a dynamic balance state, cell because
This obtains enough energy supplies, and vital movement is in normal condition.But NAD+ is also constantly decomposed, if do not supplemented
New NAD+, intracellular NADH and NAD+ quantity are constantly reduced, and cell will aging.So if supplementing new NADH, carefully
Born of the same parents return to normal condition, and function of human body keeps healthy state；NR, NMN or NADH are supplemented, is provided to allow intracellular
Portion's NADH quantity increases, the result is that cell has obtained sufficient energy supply, due to arbitrary way difference, external application, it is oral or
Injection, effect also can be different, because will undergo a quilt before entering eventually into cell interior by different arbitrary ways
The process that cell absorbs, that is, has different bioavilabilities, specifically uses which kind of arbitrary way, or supplement it is any or
Which kind compound of person, can be adjusted according to the actual situation.
Wherein, pyrroles's quinoline disodium salt (being referred to as also PQQ), it is a kind of oxidation that PQQ, which is a kind of new type water-solubility vitamin,
Reductase prothetic group, it is very rare, is present in some microorganisms, in plant and animal tissue, is not only involved in catalysis biological body
Redox reaction, but also there are some special bioactivity and physiological function, typical function is to promote into the cell
The generation of mitochondria, micro PQQ can improve metabolism and the growth function of bio-tissue, extremely precious, therefore it is in function
It with niacinamide core carbohydrates and their derivative is complementary on energy.
Based on foregoing description, in order to further preferably explain the present invention, also offer following examples:
Embodiment 1
Take niacinamide ribose (NR) (chloride or nicotinamide riboside) and two kinds of β-nicotinamide mononucleotide (NMN) changes
Close object；Or two kinds of niacinamide ribose (NR) (chloride or nicotinamide riboside) and nicotinamide adenine dinucleotide (NADH)
Compound；Or two kinds of chemical combination of niacinamide ribose (NR) (chloride or nicotinamide riboside) and pyrroloquinoline quinone disodium salt (PQQ)
Object；Or two kinds of compounds of β-nicotinamide mononucleotide (NMN) and nicotinamide adenine dinucleotide (NADH)；Or β-niacinamide list
Two kinds of compounds of nucleotide (NMN) and pyrroloquinoline quinone disodium salt (PQQ)；Or nicotinamide adenine dinucleotide (NADH) and pyrrole
Two kinds of compounds of quinoline quinone disodium salt (PQQ) are coughed up, above-mentioned any two kinds of compound combinations are formulated at one, food is made into, protects
Health food, beauty product perhaps drug in a manner of external application, oral or injection, into human body in play a role.
In the above-described embodiments, niacinamide ribose (NR) (chloride or nicotinamide riboside) is single in combination formula
Perhaps daily dosage range is as follows for the dosage of ingredient: single dose 1mg to 100000mg daily dosage or limited amount
1mg to 100000mg, including the application in food, health care product, beauty product and drug.
In the above-described embodiments, β-nicotinamide mononucleotide (NMN) dosage of single component or every in combination formula
It dosage range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, including
Application in food, health care product, beauty product and drug.
In the above-described embodiments, nicotinamide adenine dinucleotide (NADH) in combination formula the dosage of single component or
The daily dosage range of person is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg,
Including the application in food, health care product, beauty product and drug.
In the above-described embodiments, pyrroloquinoline quinone disodium salt (PQQ) dosage of single component or every in combination formula
It dosage range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, including
Application in food, health care product, beauty product and drug.
Embodiment 2
Take niacinamide ribose (NR) (chloride or nicotinamide riboside), β-nicotinamide mononucleotide (NMN) and niacinamide
Three kinds of compounds of adenine-dinucleotide (NADH)；Or take niacinamide ribose (NR) (chloride or nicotinamide riboside), β-cigarette
Three kinds of compounds of amide mononucleotide (NMN) and pyrroloquinoline quinone disodium salt (PQQ)；Or take niacinamide ribose (NR) (chloride,
Or nicotinamide riboside), three kinds of compounds of nicotinamide adenine dinucleotide (NADH) and pyrroloquinoline quinone disodium salt (PQQ)；
Or take β-nicotinamide mononucleotide (NMN), nicotinamide adenine dinucleotide (NADH) and pyrroloquinoline quinone disodium salt (PQQ) three
Kind compound；Above-mentioned any three kinds of different compound combinations are formulated at one, be made into food, health food, beauty product or
Person's drug, in a manner of external application, oral or injection, into human body in play a role；
In the above-described embodiments, niacinamide ribose (NR) (chloride or nicotinamide riboside) is single in combination formula
Perhaps daily dosage range is as follows for the dosage of ingredient: single dose 1mg to 100000mg daily dosage or limited amount
1mg to 100000mg, including the application in food, health care product, beauty product and drug.
In the above-described embodiments, β-nicotinamide mononucleotide (NMN) dosage of single component or every in combination formula
It dosage range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, including
Application in food, health care product, beauty product and drug.
In the above-described embodiments, nicotinamide adenine dinucleotide (NADH) in combination formula the dosage of single component or
The daily dosage range of person is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg,
Including the application in food, health care product, beauty product and drug.
In the above-described embodiments, pyrroloquinoline quinone disodium salt (PQQ) dosage of single component or every in combination formula
It dosage range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, including
Application in food, health care product, beauty product and drug.
Embodiment 3
Take niacinamide ribose (NR) (chloride or nicotinamide riboside), β-nicotinamide mononucleotide (NMN), niacinamide
Adenine-dinucleotide (NADH) compound combination different with pyrroloquinoline quinone disodium salt four kinds of (PQQ) is formulated at one, is done
At food, health food, beauty product perhaps drug in a manner of external application, oral or injection, into human body in play and make
With；
In the above-described embodiments, niacinamide ribose (NR) (chloride or nicotinamide riboside) is single in combination formula
Perhaps daily dosage range is as follows for the dosage of ingredient: single dose 1mg to 100000mg daily dosage or limited amount
1mg to 100000mg, including the application in food, health care product, beauty product and drug.
In the above-described embodiments, β-nicotinamide mononucleotide (NMN) dosage of single component or every in combination formula
It dosage range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, including
Application in food, health care product, beauty product and drug.
In the above-described embodiments, nicotinamide adenine dinucleotide (NADH) in combination formula the dosage of single component or
The daily dosage range of person is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg,
Including the application in food, health care product, beauty product and drug.
In the above-described embodiments, pyrroloquinoline quinone disodium salt (PQQ) dosage of single component or every in combination formula
It dosage range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, including
Application in food, health care product, beauty product and drug.
Embodiment 4
Based on pyrroloquinoline quinone (English name: pyrroloquinoline quinone, abbreviation PQQ) CAS 72909-34-
3, function is identical as pyrroles's quinoline disodium salt, therefore, can be by the pyrroloquinoline quinone disodium salt in above-described embodiment one, two, three
(PQQ) it is replaced using pyrroloquinoline quinone (PQQ) identical with its function.
In summary: the combination work of niacinamide core carbohydrates and their derivative provided by the invention and pyrroloquinoline quinone and its sodium salt
Skill, niacinamide core carbohydrates and their derivative include niacinamide ribose (NR) (chloride or nicotinamide riboside), β-niacinamide list
Nucleotide (NMN), nicotinamide adenine dinucleotide (NADH) have the function of anti-aging, and have prevention to a variety of diseases
With the effect for the treatment of；Pyrroloquinoline quinone and its sodium salt have the function of similar and functionally mutually complementary with niacinamide ribose
It fills, food additives, health care is made into pyrroloquinoline quinone or its sodium salt, combination formula by niacinamide ribose or derivatives thereof
The products such as food, beauty product and drug achieve the purpose that delaying human body caducity, beauty or treatment disease.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (6)
1. the group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt, which is characterized in that including nicotinoyl
Amine ribose (NR) (chloride or nicotinamide riboside), β-nicotinamide mononucleotide (NMN), nicotinamide adenine dinucleotide
(NADH), four kinds of different compounds of pyrroloquinoline quinone disodium salt (PQQ), by above-mentioned four kinds different compounds with any 2 kind, times
3 kinds of meaning perhaps all 4 kinds be combined into a formula and be made into food, health food, beauty product or drug, with external application, take orally
Or injection mode, into human body in play a role.
2. the group technology of niacinamide core carbohydrates and their derivative according to claim 1 and pyrroloquinoline quinone and its sodium salt,
It is replaced it is characterized in that, pyrroloquinoline quinone (PQQ) identical with its function can be used in pyrroloquinoline quinone disodium salt (PQQ).
3. the group technology of niacinamide core carbohydrates and their derivative according to claim 1 and pyrroloquinoline quinone and its sodium salt,
It is characterized in that, niacinamide ribose (NR) (chloride or nicotinamide riboside) in combination formula the dosage of single component or
The daily dosage range of person is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg,
Including the application in food, health care product, beauty product and drug.
4. the group technology of niacinamide core carbohydrates and their derivative according to claim 1 and pyrroloquinoline quinone and its sodium salt,
It is characterized in that, β-nicotinamide mononucleotide (NMN) dosage of single component or daily dosage range in combination formula
As follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg are included in food, health care
Application in product, beauty product and drug.
5. the group technology of niacinamide core carbohydrates and their derivative according to claim 1 and pyrroloquinoline quinone and its sodium salt,
It is characterized in that, nicotinamide adenine dinucleotide (NADH) dosage of single component or daily dosage in combination formula
Range is as follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg, be included in food,
Application in health care product, beauty product and drug.
6. the group technology of niacinamide core carbohydrates and their derivative according to claim 1 and pyrroloquinoline quinone and its sodium salt,
It is characterized in that, pyrroloquinoline quinone disodium salt (PQQ) dosage of single component or daily dosage range in combination formula
As follows: single dose 1mg to 100000mg, daily dosage or limited amount 1mg to 100000mg are included in food, health care
Application in product, beauty product and drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811207017.9A CN109350622A (en) | 2018-10-17 | 2018-10-17 | The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811207017.9A CN109350622A (en) | 2018-10-17 | 2018-10-17 | The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109350622A true CN109350622A (en) | 2019-02-19 |
Family
ID=65349385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811207017.9A Pending CN109350622A (en) | 2018-10-17 | 2018-10-17 | The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109350622A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110680827A (en) * | 2019-11-05 | 2020-01-14 | 深圳市龙格生技术有限公司 | Injection medicine of nicotinamide ribose derivative |
| CN110934768A (en) * | 2019-12-25 | 2020-03-31 | 深圳市龙格生技术有限公司 | Nicotinamide ribose derivative cosmetic raw material and application thereof in cosmetics |
| CN110973260A (en) * | 2019-12-11 | 2020-04-10 | 杨力 | Nicotinamide riboside-containing milk and preparation method and application thereof |
| CN111374310A (en) * | 2020-04-16 | 2020-07-07 | 上海益跬尔生物科技有限公司 | Edible compound mitochondrial energy enhancing formula |
| CN111838669A (en) * | 2020-08-07 | 2020-10-30 | 四川大学华西医院 | Nano composition for treating and improving vulnerable viscera, preparation method and application |
| CN112076203A (en) * | 2020-09-29 | 2020-12-15 | 上海元靖信息科技有限公司 | Anti-aging composition |
| CN112206237A (en) * | 2019-07-10 | 2021-01-12 | 杨维稼 | Anti-aging composition containing zinc taurate, preparation method and application thereof |
| CN112451494A (en) * | 2020-11-11 | 2021-03-09 | 武汉林宝莱生物科技有限公司 | Pyrroloquinoline quinone formula and NMN preparation formula preparation method |
| CN113170889A (en) * | 2021-05-21 | 2021-07-27 | 卢静 | Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof |
| CN114191329A (en) * | 2021-12-17 | 2022-03-18 | 百瑞全球有限公司 | Oral care additive, oral care composition, preparation method, kit and application thereof |
| CN114344455A (en) * | 2022-01-19 | 2022-04-15 | 宝莱福健康科技研究(中山)有限公司 | Preparation method and application of anti-aging composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105992521A (en) * | 2013-11-12 | 2016-10-05 | 奥索努特拉有限责任公司 | Theacrine-based supplement and method of use thereof |
| WO2017070647A1 (en) * | 2015-10-23 | 2017-04-27 | The Jackson Laboratory | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) |
-
2018
- 2018-10-17 CN CN201811207017.9A patent/CN109350622A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105992521A (en) * | 2013-11-12 | 2016-10-05 | 奥索努特拉有限责任公司 | Theacrine-based supplement and method of use thereof |
| WO2017070647A1 (en) * | 2015-10-23 | 2017-04-27 | The Jackson Laboratory | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) |
Non-Patent Citations (4)
| Title |
|---|
| 信息窗-食品伙伴网: "欧盟批准1-氯甲基烟酰胺和吡咯喹啉醌钠盐作为新型食品", 《中国食品学科》 * |
| 唐靓等: "吡咯喹啉醌研究新进展", 《食品科学》 * |
| 马雅迪编著: "《做个靓丽准妈妈》", 31 December 2004, 中国人口出版社 * |
| 高兰兴等主编: "《军队营养与食品学》", 31 October 2008, 军事医学科学出版社 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112206237A (en) * | 2019-07-10 | 2021-01-12 | 杨维稼 | Anti-aging composition containing zinc taurate, preparation method and application thereof |
| CN110680827A (en) * | 2019-11-05 | 2020-01-14 | 深圳市龙格生技术有限公司 | Injection medicine of nicotinamide ribose derivative |
| CN110973260A (en) * | 2019-12-11 | 2020-04-10 | 杨力 | Nicotinamide riboside-containing milk and preparation method and application thereof |
| CN110934768A (en) * | 2019-12-25 | 2020-03-31 | 深圳市龙格生技术有限公司 | Nicotinamide ribose derivative cosmetic raw material and application thereof in cosmetics |
| CN111374310A (en) * | 2020-04-16 | 2020-07-07 | 上海益跬尔生物科技有限公司 | Edible compound mitochondrial energy enhancing formula |
| CN111838669A (en) * | 2020-08-07 | 2020-10-30 | 四川大学华西医院 | Nano composition for treating and improving vulnerable viscera, preparation method and application |
| CN112076203A (en) * | 2020-09-29 | 2020-12-15 | 上海元靖信息科技有限公司 | Anti-aging composition |
| CN112451494A (en) * | 2020-11-11 | 2021-03-09 | 武汉林宝莱生物科技有限公司 | Pyrroloquinoline quinone formula and NMN preparation formula preparation method |
| CN113170889A (en) * | 2021-05-21 | 2021-07-27 | 卢静 | Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof |
| CN114191329A (en) * | 2021-12-17 | 2022-03-18 | 百瑞全球有限公司 | Oral care additive, oral care composition, preparation method, kit and application thereof |
| WO2023108866A1 (en) * | 2021-12-17 | 2023-06-22 | 百瑞全球有限公司 | Oral care additive, oral care composition, preparation method, kit, and application of oral care additive |
| CN114344455A (en) * | 2022-01-19 | 2022-04-15 | 宝莱福健康科技研究(中山)有限公司 | Preparation method and application of anti-aging composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109350622A (en) | The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt | |
| Schnellbaecher et al. | Vitamins in cell culture media: Stability and stabilization strategies | |
| Dienel et al. | Glucose and lactate metabolism during brain activation | |
| Stone et al. | Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide | |
| JP2851289B2 (en) | Pharmaceutical uses of glutathione derivatives | |
| May et al. | Selenium-based antihypertensives: rationale and potential | |
| EP3277675B1 (en) | Heterocyclic modulators of lipid synthesis | |
| SK11252003A3 (en) | Compositions of biochemical compounds involved in bioenergy metabolism of cells | |
| WO2020197882A1 (en) | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide | |
| Oberkersch et al. | Role of amino acid metabolism in angiogenesis | |
| Mattson et al. | Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism | |
| US20100008923A1 (en) | Organic Compounds | |
| Schmidt et al. | Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation | |
| CN107375934A (en) | Application of the composition containing the diphosphonic acid of fructose 1,6 in antineoplastic is prepared | |
| Nakano et al. | Effects of antioxidant supplements (BioPQQ™) on cerebral blood flow and oxygen metabolism in the prefrontal cortex | |
| US20030148991A1 (en) | Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system | |
| DE60006936D1 (en) | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROCHINAZOLINES, THEIR PRODUCTION, THEIR USE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| Subratty et al. | Vitamin C and urea inhibit the formation of advanced glycation end products in vitro | |
| Lemaire et al. | Differential cytostatic effects of NO donors and NO producing cells | |
| EP4147693A1 (en) | Method for enhancing energy production and metabolism in cells | |
| Yusof et al. | ROLE OF L-GLUTAMINE IN THE IN-VITRO GROWTH OF HCT-8 AND HT-29 CELL LINES | |
| JP7036324B2 (en) | Anti-blood coagulation agent, blood coagulation improving device, blood coagulation improving method, vascular endothelial cell function improving method and metabolism improving method | |
| Sawabe et al. | Tetrahydrobiopterin in intestinal lumen: Its absorption and secretion in the small intestine and the elimination in the large intestine | |
| CN111838669B (en) | Nano composition for treating and improving vulnerable viscera, preparation method and application | |
| RU2720134C1 (en) | Pharmaceutical composition for parenteral drop introduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190219 |
|
| RJ01 | Rejection of invention patent application after publication |